Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE M 75 versus LIQUID E Z PAQUE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE M 75 versus LIQUID E Z PAQUE.
HYPAQUE-M,75% vs LIQUID E-Z-PAQUE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast agent that attenuates X-rays, providing radiographic contrast due to high iodine content. It increases the density of vascular structures and tissues, allowing visualization of anatomical structures during imaging procedures.
Barium sulfate is a radiopaque agent that coats the mucosal surface of the gastrointestinal tract, attenuating X-rays and providing contrast on imaging studies.
1.2-1.5 mL/kg IV as a single dose for CT enhancement; maximum 150 mL per procedure.
Oral: 25-50 mL (barium sulfate 60% w/v) as a single dose for upper GI series; for double-contrast studies, 100-200 mL (barium sulfate 250% w/v) as a single dose. Rectal: For barium enema, 200-300 mL of a 15-20% w/v suspension instilled via enema tube.
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours in normal renal function; prolonged in renal impairment (up to 24-48 hours in anuria).
Not applicable (non-systemic agent); plasma half-life not clinically relevant.
Renal excretion: >95% unchanged via glomerular filtration; biliary/fecal: <5%.
Primarily fecal (oral route, unabsorbed); negligible renal excretion (<1% as intact drug).
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent